-
This comprehensive review on postoperative patient handoffs confirms that they are high-risk events associated with adverse patient outcomes, and permits the identification of several strategies likely to improve the process despite the incompleteness and other limitations of the existing literature.
-
This study of 537 hospitals found that those with the lowest mortality rates for acute myocardial infarction have management strategies that differ in important ways from those at hospitals with higher acute myocardial infarction mortality.
-
In a retrospective, propensity-score-matched, case-control study, investigators compared clinical outcomes and drug tolerabilities between nafcillin and cefazolin in the treatment of MSSA bacteremia. The authors found that cefazolin was as efficacious as nafcillin in the treatment of MSSA bacteremia while causing fewer adverse drug events.
-
-
In this issue: Dementia and benzodiazepines; effectiveness of omega-3 fatty acid and Ginkgo biloba supplements; and FDA actions.
-
-
-
Recurrent C. difficile infection (CDI) is a challenging condition to manage. Current guidelines estimate that 25% of patients treated for CDI experience at least 1 additional episode, with those aged 65 years or greater at highest risk.
-
Sanofi Pasteur announced September 28, 2012 a recall of 6 lots of Typhim Vi polysaccharide vaccine, the injectable "killed" vaccine. A significant portion of the stock has been shown to be insufficiently immunogenic and at risk for "low antigen content."
-
An investigation initiated after a clinician reported to the Tennessee Department of Health on September 18, 2012 the case of a patient who developed meningitis due to Aspergillus fumigatus after having received an epidural corticosteroid injection at an ambulatory surgical center quickly identified a number of other suspect cases.
